Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan

Chinese Journal of Physiology

Volumn 51, Issue 6, 2008, Pages 387-393

  Chang, Ting Ting ^a   Lêng, Chhian Hui ^a,b   Wu, Jo Yung Wei ^a   Lee, Sheng Yu ^a   Wang, Yu Shan ^a   Chen, Yi Chyan ^c   Lu, Ru Band ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Efficacy; Major depression; Milnacipran; Paroxetine; Side effect

Indexed keywords

MILNACIPRAN; PAROXETINE; CYCLOPROPANE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHINESE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CONCENTRATION LOSS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERANCE; DSM-IV; EVENING DOSAGE; FEMALE; GENERAL CONDITION IMPROVEMENT; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MORNING DOSAGE; NAUSEA; OPEN STUDY; PSYCHOMOTOR RETARDATION; SKIN DISEASE; TAIWAN; TREATMENT DURATION; TREMOR; UROGENITAL TRACT DISEASE; VOMITING; ADOLESCENT; AGED; ASIAN; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; ETHNOLOGY; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MOLECULAR STRUCTURE; PAROXETINE; TAIWAN;

EID: 66149139805     PISSN: 03044920     EISSN: 26660059     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bockting, C.L., Spinhoven, P., Koeter, M.W., Wouters, L.F. and Schene, A.H. Prediction of recurrence in recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study. J. Clin. Psychiatry. 67: 747-755, 2006.
2. Bourin, M., Chue, P. and Guillon, Y. Paroxetine: A review. CNS Drug Rev. 7: 25-47, 2001.
3. Delini-Stula, A. Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. Hum. Psychopharmacol. 15: 255-260, 2000.
4. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23: 56-62, 1960.
5. Hiemke, C. Paroxetine: pharmacokinetics and pharmacodynamics. Fortschr. Neurol. Psychiatr. 62 Suppl 1: 2-8, 1994.
6. Khun, R. Uher die Behandlung depressiver Zustande mit einen Ominodibenzyl-deriva G22355. Schiweizerische Medizinische Wochenschrift. 87: 1135-1149, 1957.
7. Ko, H.C., Lu, R.B., Shiah, I.S. and Heang, C.C. Plasma free 3-methoxy-4-hydrophenyl-glycol predicts response to fluoxetine. Biol. Psychiatry 41: 774-781, 1997.
8. Kolb, L.C. Modern Clinical Psychiatric. 9th ed. Philadelphia: W. B. Sauders Co., 1997, pp. 440.
9. Lecrubiter, Y. Milnacipran: The clinical properties of a selective serotonin and noradrenaline reuptake inhibitor SNRI. Hum. Psychopharmacol. 12: 127-134, 1997.
10. Lin, K.M. and Finder, E. Neuroleptic dosage for Asians. Am. J. Psychiatry 140: 490-491, 1983.
11. Lopez-Ibor, J., Guelfi, J.D., Pletan, Y., Tournoux, A. and Prost, J.F. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int. Clin. Psychopharmacol. 11 Suppl 4: 41-46, 1996.
12. Lu, R.B. Depression. Cont. Med. Educ. 2: 708-713, 1992.
13. Lu, R.B., Ko, H.C., Hwang, C.C. and Lin, Y.T. Comparison of the clinical efficacy and safety of fluoxetine and imipramine in majordepressive disorder. J. Am. Med. Assoc. Southeast Asia 7 Suppl: 41-45, 1991.
14. Montgomery, S.A., Prost, J.F., Solles, A. and Briley, M. Efficacy and tolerability of milnacipran: an overview. Int. Clin. Psychopharmacol. 11 Suppl 4: 47-51, 1996.
15. Montgomery, S.A., Robters, A. and Mongtomery, D.B. Depression: a long-term illness and its treatment. Proceedings from a Lundbeck Symposiom held in Washington, DC. In: The 19th CNIP Congress pp. 51-56, 28 June 1994.
16. Morishita, S. and Arita, S. Different effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age. Hum. Psychopharmacol. 19: 405-408, 2004.
17. Morishita, S. and Arita, S. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression. Hum. Psychopharmacol. 18: 479-482, 2003.
18. Morishita, S. and Arita, S. The clinical use of milnacipran for depression. Eur. Psychiatry. 18: 34-35, 2003.
19. Nierenberg, A.A., Gray, S.M. and Grandin, L.D. Mood disorders and suicide. J. Clin. Psychiatry. 62: 27-30, 2001.
20. Owens, M.J., Knight, D.L. and Nemeroff, C.B. Paroxetine binding to the rat norepinephrine transporter in vivo. Biol. Psychiatry. 47: 842-845, 2000.
21. Preskorn, S.H. Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor. J. Psychiatr. Pract. 10: 119-126, 2004.
22. Puech, A., Montgomery, S.A., Prost, J.F., Solles, A. and Briley, M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int. Clin. Psychopharmacol. 12: 99-108, 1997.
23. Puozzo, C., Albin, H., Vincon, G., Deprez, D., Raymond, J.M. and Amouretti, M. Pharmacokinetics of milnacipran in liver impairment. Eur. J. Drug. Metab. Pharmacokinet. 23: 273-279, 1998.
24. Puozzo, C. and Leonard, B.E. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int. Clin. Psychopharmacol. 11 Suppl 4: 15-27, 1996.
25. Rudorfer, M.V., Lane, E., Chang, W.H., Zhang, M. and Potter, W.Z. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Brit. J. Clin. Pharmacol. 17: 433-440, 1984.
26. Sadock, B.J. and Sadock, V.A. Synopsis of Psychiatry, 7th ed. Baltimore: Willams and Wilkins. 1994, pp. 535.
27. Sechter, D., Vandel, P., Weiller, E., Pezous, N., Cabance, F. and Tournoux, A. A comparative study of milnacipran and paroxetine in out-patients with major depression. J. Affect. Disord. 83: 233-236, 2004.
28. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R. and Dunbar, G.C. The MiniInternational Neuropsychiatric Interview M.I.N.I.: the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 59 Suppl 20: 22-33, 1998.
29. Shinji, S., Yuriko, Y., Yasushi, T., Hitoshi, O. and Takashi, A. Efficacy of milnacipran on cognitive dysfunction with post-storke depression: Preliminary open-label study. Psychiatry Clin. Neurosci. 60: 584-589, 2006.
30. Shopsin, B. and Waters, B. The pharmacotherapy of major depression syndrome. Part I: Treatment of acute depression. Psychosom. Med. 21: 554-556, 1980.
31. Stahl, S.M., Grady, M.M., Moret, C. and Briley, M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10: 732-747, 2005.
32. Sugrue, M.F. Current concepts of the mechanisms of antidepressant drugs. Pharmacol. Ser. 13: 219-247, 1981.
33. Tignol, J., Pujol-Domenech, J., Chartres, J.P., L'Eger, J.M., Pl'Etan, Y. and Tonelli, I. Double blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta. Psych. Scand. 97: 157-165, 1998.
34. Thase, M.E., Entsuah, A.R. and Rudolph, R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Brit. J. Psychiatry. 178: 234-241, 2001.
35. Yazici, O., Aricioglu, F., Gurvit, G., Ucok, A., Tastaban, Y., Canberk, O., Ozguroglu, M., Durat, T. and Sahin, D. Noradrenergic and serotoninergic depression. J. Affective. Disord. 27: 123-129, 1993.
36. Yeh, C.B., Ko, H.C. and Lu, R.B. Comparison of the clinical efficacy and safety of venlafaxine and imipramine in major depressive disorder. Taiwanese J. Psychiatry 13: 44-53, 1999.